Carlsmed develops the aprevo® personalized spine surgery platform, an AI-enabled system delivering patient-specific interbody fusion implants for lumbar fusion procedures. The company is commercializing aprevo for lumbar fusions and is developing a cervical fusion version planned to launch in 2025. Carlsmed’s implantable devices and software platforms are FDA cleared for lumbar spine fusion across anterior, lateral, and transforaminal approaches, and aprevo has received FDA Breakthrough Device designation for both lumbar and cervical devices. Management cites clinical publications showing aprevo patient-specific implants improve outcomes, and says its AI-enabled platform and business model enable rapid scaling of production to meet growing demand. Carlsmed’s mission is to improve outcomes and decrease healthcare costs for spine surgery, advancing the standard of care one patient at a time. Carlsmed produces aprevo®, an FDA‑cleared personalized spinal fusion device designed and manufactured for individual patients with spinal alignment correction built into the implant. The company leverages patient data and proprietary digital technologies, including machine learning and artificial intelligence, to create surgeon- and patient-specific implants. Carlsmed's stated mission is to improve outcomes and decrease the cost of healthcare for spine surgery by replacing mass-produced stock implants with bespoke devices. The company plans to use proceeds from its recent financing to ramp commercialization of aprevo® and scale adoption. Carlsmed closed an oversubscribed $30M Series B to support those commercialization efforts. Leadership additions tied to the round include Robert Mittendorff, MD, MBA joining the board and Widya Mulyasasmita joining as a board observer. Carlsmed develops the aprevo family of spine deformity correction devices, combining digital planning and personalized implants. Its platform uses machine learning and prior outcomes data to create optimized surgical plans and patient-specific aprevo implants. The company recently launched its Breakthrough aprevo devices and is focused on meeting surgeon and patient demand. Carlsmed's core product is a digital + surgical solution intended to enable superior correction of adult spinal deformities. The company says its mission is to help surgeons obtain better results at lower cost and help adults regain active lifestyles. Carlsmed is based in San Diego and has closed a $10M Series A to commercialize the aprevo devices. Carlsmed leverages machine learning and prior outcomes data to personalize treatment for complex adult spinal deformities. Its proprietary aprevo system creates surgical plans and patient-specific devices tailored to each individual's medical situation. The company positions the system to improve results while lowering treatment costs and helping adults regain active lifestyles. Carlsmed is incubating at EvoNexus and was named a Connect | San Diego Venture Group 2020 Cool Company. It recently closed an oversubscribed $2.5M seed round to accelerate the clinical launch of the aprevo system. The company also added Alexander Arrow as CFO and Shariq Hussain as CIO to build infrastructure and scale operations to meet clinical demand.

Total raised

$95M

Funding rounds

4

Latest round

Series C

Latest activity

Mar 2024